Abstract: The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and interleukin 6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and interleukin 6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and interleukin 6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein proteasome subunit alpha 3 (PSA3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSA3 in said sample. Measurement of PSA3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein PDX1 (peroxiredoxin 1) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring PDX1 in said sample. Measurement of PDX1 can, e.g., be used in the early detection or diagnosis of breast cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein RS15A (ribosomal protein S15a) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring RS15A in said sample. Measurement of RS15A can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein CBP2 (collagen-binding protein 2) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring CBP2 in said sample. Measurement of CBP2 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The use of polyalkylene oxide modified reagents is disclosed in a method for the detection of an analyte or in suitable reagent kits for such methods.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of RF and interleukin-6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with RF and interleukin-6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising RF and interleukin-6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Abstract: The invention relates to a method of identifying N-terminal proBNP in a sample with at least two antibodies that detect different epitopes of the N-terminal proBNP. The method is used to differentiate or classify samples of healthy individuals and samples of patients of NYHA classes I to IV. The invention further relates to recombinant N-terminal proBNP, its use as standard in a method of identifying N-terminal proBNP, to antibodies that detect recombinant N-terminal proBNP and to their production.

Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.

Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of spermidine synthase (SPEE) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring SPEE in the sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of breast cancer.

Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of ubiquitin-conjugating enzyme E2N (UBC13) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring UBC13 in the sample. Measurement of UBC13 can, e.g., be used in the early detection or diagnosis of breast cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PSE3 (proteasome activator subunit 3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSE3 in said sample. Measurement of PSE3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein RLA-0 (60S acidic ribosomal protein P0) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring RLA-0 in said sample. Measurement of RLA-0 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: A local probe measuring device is provided for effecting local measurements of a sample. This device includes first and second local probes for local measurements with respect to a sample or a reference surface. A measurement condition adjustment arrangement is adapted to commonly adjust first and second measurement conditions of the respective first and second local probes with respect to the sample or the reference surface. A detection arrangement is provided that includes first detection arrangement associated with the first local probe adapted to independently detect first measurement data referring to local measurements reflected by first local probe and a second detection arrangement associated with the second local probe adapted to independently detect second measurement data referring to local measurements effected by second local probe. Further, methods for effecting local measurements and local manipulations using multiple local probes are provided.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein SPEE (sperrnidine synthase) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring SPEE in said sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PLST (T-plastin) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PLST in said sample. Measurement of PLST can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PRN3/ILEU and/or unbound PRN3 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PRN3/ILEU and/or unbound PRN3 in said sample. Measurement of PRN3/ILEU and/or unbound PRN3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein MASP in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring MASP in said sample. Measurement of MASP can, e.g., be used in the early detection or diagnosis of colorectal cancer.